GlassScriptPhysician profile
Mona M Patel
NPI 1740257880
$2,528.23
in general payments reported to CMS, 2019-2025
24 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $125 · 2022: $192 · 2023: $484 · 2024: $539 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $341.04 | 2022-2025 | Caplyta |
| Abbvie INC. | $302.85 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $252.82 | 2022-2025 | Infuse |
| Takeda Pharmaceuticals U.S.A., INC. | $228.85 | 2019-2025 | Trintellix |
| Allergan, INC. | $224.02 | 2019-2020 | |
| Neos Therapeutics, LP | $208.63 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Tris Pharma INC | $145.68 | 2019-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $131.92 | 2019-2025 | Rexulti |
| Lundbeck LLC | $93.35 | 2019-2025 | Rexulti |
| Shire North American Group INC | $83.94 | 2019 | |
| Corium, LLC | $76.95 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $74.56 | 2019-2020 | |
| Axsome Therapeutics, INC. | $70.55 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $42.60 | 2019-2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $41.25 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $38.56 | 2019-2020 | |
| Alkermes, INC. | $32.62 | 2023 | Lybalvi |
| Collegium Pharmaceutical, INC. | $29.29 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $25.41 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $21.75 | 2025 | Qelbree |
| Noven Pharmaceuticals, INC. | $20.20 | 2024 | Xelstrym |
| Adlon Therapeutics L.P. | $15.79 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.65 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.